🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Teresa M. Petrella

Sunnybrook Health Science Centre

ORCID: 0000-0002-2933-1861

Also affiliated with Health Sciences Centre

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.”.

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9501

N/A

1.3DataRank · unranked

18 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Teresa M. Petrella +15 more

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002535

N/A

0.520DataRank · unranked

31 citations

Ni Kang, Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen, Omid Hamid +16 more

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants, and association with outcome: E1609 study analysis.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.5_suppl.60

N/A

0DataRank · unranked

1 citations

Sandra J. Lee, Ni Kang, F. Stephen Hodi, Uma N. M. Rao, Gary I. Cohen +5 more

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-1141

N/A

0DataRank · unranked

102 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

A tailored approach to horizon scanning for cancer medicines

Journal of Cancer Policy(2023)10.1016/j.jcpo.2023.100441

N/A

0DataRank · unranked

4 citations

Yat Hang To, Marliese Alexander, Karen Trapani, Paolo A. Ascierto, Sophy Athan +28 more

Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

(2023)10.1158/2159-8290.c.6549583.v1

N/A

0DataRank · unranked

0 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more